Research programme: autoimmune disorder therapeutics - Gliknik

Drug Profile

Research programme: autoimmune disorder therapeutics - Gliknik

Alternative Names: GL-2045

Latest Information Update: 12 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gliknik
  • Class Recombinant fusion proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 10 Aug 2015 GL 2045 receives Orphan Drug status for Chronic inflammatory demyelinating polyradiculoneuropathy in USA
  • 30 Sep 2013 GL-2045 licensed to Pfizer worldwide
  • 09 Oct 2012 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top